Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 16/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14037800 | 1.00 | CXCR4 (0.46) | CXCR4CYP2D6CHRM3CYP3A4CYP2C8 | |
| SCHEMBL30584967 | 1.00 | CXCR4 (0.46) | CXCR4CYP2D6CHRM3CYP3A4CYP2C8 | |
| SCHEMBL3315162 | 0.90 | CXCR4 (0.40) | CXCR4CYP2D6CHRM3CYP3A4CYP2C8 | |
| SCHEMBL10367296 | 0.84 | CXCR4 (0.51) | CXCR4CYP2D6 | |
| SCHEMBL24858718 | 0.83 | CYP2D6 (0.43) | CXCR4CYP2D6HDAC1HDAC6 | |
| SCHEMBL3314390 | 0.83 | HDAC1 (0.44) | CXCR4CYP2D6HDAC1HDAC6 | |
| SCHEMBL21202393 | 0.83 | CYP2D6 (0.43) | CXCR4CYP2D6HDAC1HDAC6 | |
| SCHEMBL26337669 | 0.82 | CXCR4 (0.52) | CXCR4CYP2D6 | |
| SCHEMBL3950796 | 0.82 | HDAC1 (0.43) | CXCR4CYP2D6HDAC1HDAC6 | |
| SCHEMBL14071365 | 0.81 | CYP2D6 (0.42) | CXCR4CYP2D6HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12534475-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-27 | — | — | US | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-12077546-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4324834-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-21 | — | — | EP | disclosed |
| CN-117177977-A | Bicyclic pyridine derivatives | 住友制药株式会社 | 2023-12-05 | — | — | CN | disclosed |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2010-04-29 | — | — | US | disclosed |
| US-7629337-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7452994-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-7183273-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2007-02-27 | — | — | US | disclosed |
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2006-11-23 | — | — | US | disclosed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| EP-1163238-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056729-A1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | CXCR4 2/4885CYP2D6 934/4885CHRM3 241/4885 |
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYP2B6 | CXCR4 153/4885CYP2D6 9/4885CHRM3 267/4885 |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | CXCR4 232/4885CYP2D6 156/4885CHRM3 233/4885 |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CXCR4, CCR5, CXCR3 | CXCR4 1/4885CYP2D6 3280/4885CHRM3 814/4885 |
| US-12077546-B2 | Bicyclic pyridine derivative | CBR1, CBR3, CYB5R3 | CXCR4 232/4885CYP2D6 156/4885CHRM3 233/4885 |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | CXCR4 232/4885CYP2D6 156/4885CHRM3 233/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | CXCR4 2553/4885CYP2D6 4681/4885CHRM3 4868/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | CXCR4 2553/4885CYP2D6 4681/4885CHRM3 4868/4885 |
| US-12534475-B2 | Bicyclic pyridine derivative | CBR1, CYP2B6, CBR3 | CXCR4 127/4885CYP2D6 7/4885CHRM3 495/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | CXCR4 2/4885CYP2D6 946/4885CHRM3 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.